丘鈦科技(01478.HK)完成參與挪威上市公司POLIGHT ASA私募配售
格隆匯6月5日丨丘鈦科技(01478.HK)公告,董事會欣然宣佈,2025年4月15日,公司與一家於奧斯陸證券交易所上市的挪威公司poLight簽署投資協議,據此,poLight有條件同意發行,而公司有條件同意以每股2.69挪威克朗價格認購poLight擬發行63,743,112股配售股份,總代價約爲171,469,000挪威克朗(相當於約人民幣121,721,000元)(即私募配售)。
於2025年6月4日,私募配售事項已完成,合共63,743,112股配售股份已發行予公司,相當於於私募配售完成後經擴大poLight已發行股份總數約32.97%。私募配售乃以公司的內部資源提供資金。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.